Panacea-ml News
6 articles
growth-positive
PharmStars Announces the First Startup from Israel to Graduate from its Accelerator Program: Panacea-ml
Panacea-ml, an Israeli startup, has graduated from PharmStars, a pharma-focused accelerator for digital health startups. The company, which focuses on revolutionizing clinical trial design and clinical development decision-making with cutting-edge explainable AI, was part of the Spring 2024 cohort focused on Digital Innovations in Oncology. The graduation marks the successful completion of PharmStars 10-week educational and mentoring program, PharmaU. The program prepares startups to effectively engage with pharma companies as clients and partners.
Partners
growth-positive
PharmStars Announces Spring 2024 Graduates: 10 Digital Health Startups Complete PharmStars’ Pharma-focused Accelerator
PharmStars, a pharma-focused accelerator for digital health startups, has announced the graduation of 10 startups from its Spring 2024 program. The program, which focused on Digital Innovations in Oncology, included a 10-week educational and mentoring program called PharmaU. The graduating startups, which were selected from applicants from 16 countries, each offer a unique digital health solution related to digital innovations in oncology. The startups presented their solutions to PharmStars’ pharma members at a Showcase Event in Boston, and participated in one-on-one meetings with them.
CustomersPartnersExpand
growth-positive
The program that will help startups in the medical field to save lives
Predicta Med, an Israeli startup, is developing an AI-based platform for early detection and treatment of autoimmune diseases. The company was founded in 2020 and has since partnered with institutions such as Maccabi Health Services Research Institute and US hospitals including Cedars Sinai, Mayo Clinic, and Stanford. Predicta Med has raised over $4.5 million in its previous funding round and is currently closing a Seed round with strategic investors including Cedars Sinai, Mayo Clinic, leading funds in the field, and grants from Google and the Israel Innovation Authority.
InvestmentPartners
growth-positive
10 startups complete first cohort of SHAAR- Shaare Zedek - Arieli Healthcare innovation hub | CTech
Shaare Zedek Medical Center and investment firm Arieli Capital have launched the first cohort of their innovation hub, SHAAR. The hub, located within Shaare Zedek Medical Center, provides startups with immediate proximity to physicians, data, and medical departments. Ten startups in the Seed to A stages were selected for the first cohort, which concluded last week. The program included 440 business meetings and collaboration opportunities for clinical trials partnerships and funding opportunities. The selected companies tackled various medical concerns, such as lung cancer, brain stents, and post-surgical infections.
InvestmentPartners
growth-positive
Sanara Ventures adds two medtech startups to tech incubator | CTech
Sanara Ventures has added two new Israeli startups, Panacea and ActiveAging, to its technology incubator. Panacea has developed a software system for optimizing clinical trials, while ActiveAging has developed an AI-based platform for managing personalized health benefits. Sanara Ventures focuses on startups in the pre-seed, Seed, and round A stages and has over 20 portfolio companies. They have also launched Sanara Capital, raising $100 million with Philips to invest in more advanced stage startups.
PartnersInvestment
growth-positive
Ben-Gurion University Researchers Develop Machine Learning Platform to Streamline Clinical Trials
Researchers at Ben-Gurion University of the Negev (BGU) have developed a novel platform to streamline clinical trials, lower costs, and increase the efficiency and success rate of the drug or medical device development process. The technology has been licensed for further development and commercialization to Panacea, a new company founded by BGN Technologies, the technology transfer company of BGU, and Prof. Boaz Lerner of the BGU Department of Industrial Engineering and Management, and Panaceas scientific founder. The new platform leverages machine learning to optimize a clinical trials chances of success. The technology has already been used in clinical studies of several neurodegenerative diseases and has demonstrated high performance.
PartnersInvestment
